Please visit answersincme.com/QHX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal oncology discusses frontline chemoimmunotherapeutic regimens for unresectable advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Upon completion of this activity, participants should be better able to: Review guideline-recommended preferred frontline treatment regimens for unresectable advanced gastric or GEJ adenocarcinoma; Discuss clinical profiles of approved and late-stage emerging frontline immunotherapy-based chemotherapy combination regimens for unresectable advanced gastric or GEJ adenocarcinoma; and Outline practical considerations for optimizing treatment with frontline immunotherapy-based chemotherapy combination regimens in patients with unresectable advanced gastric or GEJ adenocarcinoma.